Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
102 hedge funds and large institutions have $220M invested in Chinook Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 18 reducing their positions, and 15 closing their positions.
134% more call options, than puts
Call options by funds: $2.29M | Put options by funds: $979K
128% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 18
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
15% more funds holding
Funds holding: 89 → 102 (+13)
5% less capital invested
Capital invested by funds: $232M → $220M (-$11.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.8M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.75M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$6.24M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.65M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$16.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$11.4M |
| 3 |
Jennison Associates
New York
|
-$11.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.46M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$3.82M |
KDNY Hedge Fund Activity: Q2 2016 in Review
102 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2016, worth a combined $220M — down 5.1% from $232M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KDNY positions and 15 closed out — a net gain of 14 holders — while 41 added to existing stakes and 18 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $18.8M. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $16.9M sold.
- 102 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2016, up from 89 in Q1 2016.
- Funds reported $220M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2016, down 5.1% quarter-over-quarter.
- 29 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2016 and 15 closed out, a net change of +14 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2016 was Wellington Management Group, an estimated $18.8M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2016 was Foresite Capital Management II, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2016.